Platelet and leukocyte ROS production and lipoperoxidation are associated with high platelet reactivity in Non-ST elevation myocardial infarction (NSTEMI) patients on dual antiplatelet treatment

Atherosclerosis

Volumn 231, Issue 2, 2013, Pages 392-400

  Becatti, Matteo ^a   Fiorillo, Claudia ^a   Gori, Anna Maria ^a   Marcucci, Rossella ^a   Paniccia, Rita ^a   Giusti, Betti ^a   Violi, Francesco ^b   Pignatelli, Pasquale ^b   Gensini, Gian Franco ^a   Abbate, Rosanna ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

High platelet reactivity; Leukocytes; Lipoperoxidation; ROS production

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CLOPIDOGREL; REACTIVE OXYGEN METABOLITE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; LEUKOCYTE; LEUKOCYTE COUNT; LIPID PEROXIDATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; THROMBOCYTE; TREATMENT RESPONSE;

HIGH PLATELET REACTIVITY; LEUKOCYTES; LIPOPEROXIDATION; ROS PRODUCTION;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; BLOOD PLATELETS; CELL SEPARATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKOCYTES; LIPID PEROXIDATION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEPHELOMETRY AND TURBIDIMETRY; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; REACTIVE OXYGEN SPECIES; TICLOPIDINE;

EID: 84888103660     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.09.030     Document Type: Article

References (44)

1. Parodi G., Marcucci R., Valenti R., et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011, 306:1215-1223.
2. Gori A.M., Marcucci R., Migliorini A., et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008, 52:734-739.
3. Marcucci R., Gori A.M., Paniccia R., et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009, 119:237-242.
4. Ferreiro J.L., Homs S., Berdejo J., et al. Clopidogrel pretreatment in primary percutaneous coronary intervention: prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery. Thromb Haemost 2013, 110(1).
5. Marcucci R., Gori A.M., Paniccia R., et al. Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy. Atherosclerosis 2007, 195:e217-e223.
6. Giusti B., Gori A.M., Marcucci R., et al. Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment. Atherosclerosis 2008, 196:341-348.
7. Cecchi E., Marcucci R., Paniccia R., et al. Effect of blood hematocrit and erythrocyte deformability on adenosine 5'-diphosphate platelet reactivity in patients with acute coronary syndromes on dual antiplatelet therapy. Am J Cardiol 2009, 104:764-768.
8. Gori A.M., Cesari F., Cinotti S., et al. The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients. Atherosclerosis 2009, 202:255-262.
9. Marcucci R., Cesari F., Cinotti S., et al. ADAMTS-13 activity in the presence of elevated von Willebrand factor levels as a novel mechanism of residual platelet reactivity in high risk coronary patients on antiplatelet treatment. Thromb Res 2008, 123:130-136.
10. Ferroni P., Vazzana N., Riondino S., Cuccurullo C., Guadagni F., Davì G. Platelet function in health and disease: from molecular mechanisms, redox considerations to novel therapeutic opportunities. Antioxid Redox Signal 2012, 17:1447-1485.
11. Salvemini D., de Nucci G., Gryglewski R.J., Vane J.R. Human neutrophils and mononuclear cells inhibit platelet aggregation by releasing a nitric oxide-like factor. Proc Natl Acad Sci U S A 1989 Aug, 86(16):6328-6332.
12. Bressler N.M., Broekman M.J., Marcus A.J. Concurrent studies of oxygen consumption and aggregation in stimulated human platelets. Blood 1979, 53:167-178.
13. Krotz F., Sohn H.Y., Pohl U. Reactive oxygen species: players in the platelet game. Arterioscler Thromb Vasc Biol 2004, 24:1988-1996.
14. Pignatelli P., Carnevale R., Di Santo S., et al. Inherited human gp91phox deficiency is associated with impaired isoprostane formation and platelet dysfunction. Arterioscler Thromb Vasc Biol 2011, 31:423-434.
15. Krötz F., Sohn H.Y., Gloe T., et al. NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood 2002, 100:917-924.
16. Violi F., Pignatelli P. Platelet oxidative stress and thrombosis. Thromb Res 2012, 129:378-381.
17. Burch J.W., Burch P.T. Glutathione disulfide production during arachidonic acid oxygenation in human platelets. Prostaglandins 1990, 39:123-134.
18. Freedman J.E., Keaney J.F. Nitric oxide and superoxide detection in human platelets. Methods Enzymol 1999, 301:61-70.
19. Marcus A.J., Silk S.T., Safier L.B., Ullman H.L. Superoxide production and reducing activity in human platelets. JClin Invest 1977, 59:149-158.
20. Stuart M.J., Holmsen H. Hydrogen peroxide, an inhibitor of platelet function: effect on adenine nucleotide metabolism, and the release reaction. Am J Hematol 1977, 2:53-63.
21. Singh D., Greenwald J.E., Bianchine J., Metz E.N., Sagone A.L. Evidence for the generation of hydroxyl radical during arachidonic acid metabolism by human platelets. Am J Hematol 1981, 11:233-240.
22. Krotz F., Sohn H.Y., Gloe T., et al. NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood 2002, 100:917-924.
23. Seno T., Inoue N., Gao D., et al. Involvement of NADH/NADPH oxidase in human platelet ROS production. Thromb Res 2001, 103:399-409.
24. Loscalzo J. Oxidant stress: a key determinant of atherothrombosis. Biochem Soc Trans 2003, 31:1059-1061.
25. 2-reactive species activate primed platelets in human whole blood. Am J Physiol 1993, 264:1582-1587.
26. Cerwinka W.H., Cooper D., Krieglstein C.F., Ross C.R., McCord J.M., Granger D.N. Superoxide mediates endotoxin-induced platelet-endothelial cell adhesion in intestinal venules. Am J Physiol Heart Circ Physiol 2003, 284:535-541.
27. Watt J., Ewart M.A., Greig F.H., Oldroyd K.G., Wadsworth R.M., Kennedy S. The effect of reactive oxygen species on whole blood aggregation and the endothelial cell-platelet interaction in patients with coronary heart disease. Thromb Res 2012, 130:210-215.
28. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003, 41:961-965.
29. Buonamici P., Marcucci R., Migliorini A., et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007, 49:2312-2317.
30. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. Hypertension 2003, 21:1779-1786. ESH/ESC Hypertension Guidelines Committee.
31. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adult (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
32. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003, 26:5-20.
33. World Medical Association Declaration of Helsinki Recommendations guiding physicians in biomedical research involving human subjects. Cardiovasc Res 1997, 35:2-3.
34. Becatti M., Prignano F., Fiorillo C., et al. The involvement of Smac/DIABLO, p53, NF-kB, and MAPK pathways in apoptosis of keratinocytes from perilesional vitiligo skin: protective effects of curcumin and capsaicin. Antioxid Redox Signal 2010, 13:1309-1321.
35. Becatti M., Taddei N., Cecchi C., et al. SIRT1 modulates MAPK pathways in ischemic-reperfused cardiomyocytes. Cell Mol Life Sci 2012, 69:2245-2260.
36. Bass D.A., Parce J.W., Dechatelet L.R., Szejda P., Seeds M.C., Thomas M. Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J Immunol 1983, 130:1910-1917.
37. Prignano F., Pescitelli L., Becatti M., et al. Ultrastructural and functional alterations of mitochondria in perilesional vitiligo skin. J Dermatol Sci 2009, 54:157-167.
38. Drummen G.P., van Liebergen L.C. Op den Kamp JA, Post JA. C11-BODIPY(581/591), an oxidation-sensitive fluorescent lipid peroxidation probe: (micro)spectroscopic characterization and validation of methodology. Free Radic Biol Med 2002, 33:473-490.
39. Leo R., Praticò D., Iuliano L., et al. Platelet activation by superoxide anion and hydroxyl radicals intrinsically generated by platelets that had undergone anoxia and then reoxygenated. Circulation 1997, 95:885-891.
40. Basili S., Pignatelli P., Tanzilli G., et al. Anoxia-reoxygenation enhances platelet thromboxane A2 production via reactive oxygen species-generated NOX2: effect in patients undergoing elective percutaneous coronary intervention. Arterioscler Thromb Vasc Biol 2011, 31:1766-1771.
41. Pignatelli P., Sanguigni V., Lenti L., et al. gp91phox-dependent expression of platelet CD40 ligand. Circulation 2004, 110:1326-1329.
42. Violi F., Pignatelli P., Basili S. Nutrition, supplements, and vitamins in platelet function and bleeding. Circulation 2010, 121:1033-1044.
43. Raad H., Paclet M.H., Boussetta T., et al. Regulation of the phagocyte NADPH oxidase activity: phosphorylation of gp91phox/NOX2 by protein kinase C enhances its diaphorase activity and binding to Rac2, p67phox, and p47phox. FASEB J 2009, 23:1011-1022.
44. Barygina V.V., Becatti M., Soldi G., et al. Altered redox status in the blood of psoriatic patients: involvement of NADPH oxidase and role of anti-TNF-α therapy. Redox Rep 2013, 18:100-106.